May 14, 2024 Uncategorized BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 Read More
May 3, 2024 Uncategorized BetterLife Announces Intent to Complete Private Placement of Units Read More
April 11, 2024 Uncategorized BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Read More
April 3, 2024 Uncategorized BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non- hallucinogenic LSD-based Drug Candidate BETR-001 Read More
March 4, 2024 Uncategorized BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University Read More
January 2, 2024 Uncategorized BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001 Read More